Sonnet has treated 7 patients over 2 months on average and expects to enroll up to 18 patients with unresectable, metastatic LMS or LPS in this open-label, single-arm expansion cohort. Patients ...

Anthropic has launched its most advanced AI model yet, Claude 3.7 Sonnet. The model introduces hybrid reasoning, a new approach that allows it to respond quickly and also to pursue more intensive ...

This week, OpenAI launched its GPT 4.5 language mode, Claude wasn't far behind either with Sonnet 3.7 rollout, Meta AI starts plan on bringing a standalone AI app and more. OpenAI has launched its ...

Anthropic has officially entered the high-tier AI subscription space with the launch of Claude Max, a new premium plan offering advanced features for professionals who rely heavily on artificial ...

The latest price target for Sonnet BioTherapeutics (NASDAQ:SONN) was reported by Chardan Capital on April 7, 2025. The analyst firm set a price target for $20.00 expecting SONN to rise to within ...